Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-09-11
2007-09-11
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S204100, C424S205100, C424S233100, C435S235100, C435S456000, C514S040000
Reexamination Certificate
active
10743813
ABSTRACT:
Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.
REFERENCES:
patent: 5368844 (1994-11-01), Gaffar et al.
patent: 5369095 (1994-11-01), Kee et al.
patent: 5789244 (1998-08-01), Heidrun et al.
patent: 6165779 (2000-12-01), Engler et al.
patent: 2002/0169138 (2002-11-01), Kunz et al.
patent: 1-245159 (1989-09-01), None
patent: WO97/25072 (1997-07-01), None
patent: WO 02/40630 (2002-05-01), None
Zhang et al (Cancer Res. 62: 3743-3750, 2002).
Mullen et al (Oncologist 7:106-119, 2002).
Watanabe et al (Int. J. Cancer 92: 712-717, 2001).
Connor et al (Gene Therapy 8: 41-48, 2001).
Boer et al (Biochem. Biophys Res. Comm. 166(1): 91-98, 1983).
Sedzik et al (NeuroReport 11(11): 2559-2563, 2000).
Derek Raghavan et al., “Biology and Management of Bladder Cancer”, N. Engl. J. Med., 322, 16, pp. 1129-1138 (1990).
Simon F. Brewster et al., “Gene Therapy in Urological Oncology: Principles, Strategies and Potential”, Eur. Urol. 25, pp. 177-182 (1984).
Rei Takahashi et al., “The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells”, Natl. Acad. Sci USA 88, pp. 5257-5261 (1991).
Steven A. Rosenberg, “The Immunotherapy and Gene Therapy of Cancer”, J. Clin. Oncol., 10, pp. 180-199 (1992).
C. Bass et al., “Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo”, Cancer Gene Therapy 2, 2, pp. 97-104 (1995).
Bernard D. Morris, Jr. et al., “Adenoviral-Mediated Gene Transfer to Bladder in vivo”, Urology, 152, pp. 506-550 (1994).
Y. Blixt et al., “Enhancement of intracellular uncoating of adenovirus in HeLa cells in the presence of benzyl alcohol as a membrane fluidizer”, Virol., 129, pp. 265-277 (1993).
Frederick C. Monson et al., “Indigocarmine as a Quantitative Indicator of Urothelial Integrity”, J. Urol., 145, pp. 842-845 (1992).
C.L. Parsons et al., “Bladder Surface Glycosaminoglycans: an Epithelial Permeability Barrier”, J. Urol., 143, pp. 139-142 (1990).
D. Robert Siemens et al., “Evaluation of Gene Transfer Efficiency by Viral Vectors to Murine Bladder Epithelium”, J. Urol., 165, pp. 667-671 (2001).
Mizamura, et al., “Plates for detection of antibodies to Newcastle disease virus and octyl-glucoside solubilization of virus antigen”, Database CAPLUS on STN, No. 1990:115384, Abstract Only, 1990.
Zhang, et al., “Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel”, Cancer Research, vol. 62, pp. 3743-3750, 2002.
Connor, et al., “Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium”, Gene Therapy, vol. 8, pp. 41-48, 2001.
Watanabe, et al,. “Adenovirus-Mediated Gene Therapy for Bladder Cancer in an Orthotopic Model Using a Dominant Negative H-RASMutant”, Int. J. Cancer, vol. 92, pp. 712-717, 2001.
Mullen, et al., “Viral Oncolysis”, The Oncologist, vol. 7, pp. 106-119, 2002.
Boer, et al., “Solubilization of Ligand-Stabilized Vasopressin Receptors from Plasma Membranes of Bovine Kidney and Rat Liver”, Biochem. Biophys. Res. Comm., vol. 116, No. 1, pp. 91-98, 1983.
Sedzik, et al., “Solubilization of PNS myelin membrane proteins by detergents”, Membrane Biophysics and Biochemistry, vol. 11, No. 11, pp. 2559-2563, 2000.
Kirn, “Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer”, Oncogene, vol. 19, pp. 6660-6669, 2000.
Rangel, et al,. “Taxol and taxotere in bladder cancer: in vitro activity and urine stability”, Cancer Chemother. Pharmacol., vol. 33, pp. 460-464, 1994.
Loughlin, et al., “The Use of Hydrogen Peroxide to Enhance the Efficacy of Doxorubicin Hydrocloride in a Murine Bladder Tumor Cell Line”, H. Urology, vol. 165, pp. 1300-1304, 2001.
Supplementary partial European Search report for European patnet ppplication No. 03800237.4.
Connor, R.J., et al., “Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium”,Gene Therapy,2001, 8:41-48, MacMillian Press Ltd., Basingstoke, GB.
Zhang, J., et al., “Identification of human uroplakin II promoter and its use in the construction of CG8840, a urotherlium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel”,Cancer Research,Jul. 1, 2002, 62(13):3743-3750, American Association for Cancer Research, Baltimore, MD.
Frey David
Memarzadeh Bahram
Ramesh Nagarajan
Yu De-Chao
Cell Genesys Inc.
Haley Jr. James F.
Ropes & Gray LLP
Schnizer Richard
LandOfFree
Methods and reagents for the enhancement of virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for the enhancement of virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for the enhancement of virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781169